Apellis Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
100 FIFTH AVENUE, WALTHAM, MA, 02451
Mailing Address
100 FIFTH AVENUE, WALTHAM, MA, 02451
Phone
617-977-5700
Fiscal Year End
1231
EIN
271537290
Financial Overview
FY2025
$705.11M
Total Liabilities
$370.15M
Stockholders' Equity
$0.18
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 3 Initial insider ownership report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 10-K Annual financial report | February 24, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
Insider Trading
STRONG SELL
8 insiders
26 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.